Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

Research output: Contribution to journalArticle

Standard

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. / Carlsson, Fredrika; Adler, SP; Lamarre, A; Ohlin, Mats.

In: Vaccine, Vol. 26, No. 1, 2007, p. 41-46.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

AU - Carlsson, Fredrika

AU - Adler, SP

AU - Lamarre, A

AU - Ohlin, Mats

PY - 2007

Y1 - 2007

N2 - Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy.

AB - Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy.

KW - Viral/blood

KW - Cytomegalovirus Vaccines/immunology

KW - Epitope Mapping

KW - Humans

KW - Immunization

KW - Protein Structure

KW - Antibodies

KW - Tertiary

KW - Vaccines

KW - Attenuated/immunology

KW - Synthetic/immunology

KW - Viral Envelope Proteins/chemistry

KW - Viral Envelope Proteins/immunology

U2 - 10.1016/j.vaccine.2007.10.048

DO - 10.1016/j.vaccine.2007.10.048

M3 - Article

VL - 26

SP - 41

EP - 46

JO - Vaccine

T2 - Vaccine

JF - Vaccine

SN - 1873-2518

IS - 1

ER -